Abstract
Sodium glucose transporter-2 inhibitors dapagliflozin and empagliflozin are useful to prevent hospitalizations and mortality among heart failure with reduced ejection fraction (HFrEF) patients. However, no clinical trials have been performed to assess comparative performance of these drugs. The objective of this project was to compare the cost-effectiveness of dapagliflozin and empagliflozin for treatment of HFrEF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
